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ABSTRACT
Background
Bilharzia is one of the major parasitic infections affecting the public health and
socioeconomic circumstances in (sub) tropical areas. Its causative agents are schistosomes.
Since these worms remain in their host for decades, they have developed mechanisms to evade
or resist the immune system. Like several other parasites, their surface membranes are coated
with a protective layer of glycoproteins that are anchored by a lipid modification.
Methods and Findings
We studied the release of glycosyl-phosphatidylinositol (GPI)-anchored proteins of S. mansoni
and found them in the circulation associated with host lipoprotein particles. Host cells
endocytosed schistosomal GPI-anchored proteins via their lipoprotein receptor pathway,
resulting in disturbed lysosome morphology. In patients suffering from chronic schistosomiasis,
antibodies attacked the parasite GPI-anchored glycoproteins that were associated with the
patients’ own lipoprotein particles. These immunocomplexes were endocytosed by cells
carrying an immunoglobulin-Fc receptor, leading to clearance of lipoproteins by the immune
system. As a consequence, neutral lipids accumulated in neutrophils of infected hamsters and
in human neutrophils incubated with patient serum, and this accumulation was associated with
apoptosis and reduced neutrophil viability. Also, Trypanosoma brucei, the parasite that causes
sleeping sickness, released its major GPI-anchored glycoprotein VSG221 on lipoprotein
particles, demonstrating that this process is generalizable to other pathogens/parasites.
Conclusions
Transfer of parasite antigens to host cells via host lipoproteins disrupts lipid homeostasis in
immune cells, promotes neutrophil apoptosis, may result in aberrant antigen presentation in
host cells, and thus cause an inefficient immune response against the pathogen.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Schistosomiasis, also known as bilharzia, is a chronic
disease caused by parasitic Schistosoma ﬂatworm species [1]
that affects more than 200 million people worldwide. The
schistosome is a prime example of a complex multicellular
organism that can ﬂourish in human hosts for decades
despite the development of a pronounced immune response.
The molecular basis for the prolonged survival of adult
schistosomes is an outstanding issue [2].
The major surface antigens of adult schistosomes are
tightly associated with the extracellular leaﬂet of the outer
membranes by a glycosyl-phosphatidylinositol (GPI) anchor
[3,4]. GPI-anchored proteins are abundant in parasites and
have an important role in cell viability and defence against
the host immune system [5,6]. They can be shed into the
medium by the action of proteases or phospholipases [7] or
released on membranous particles [8 11]. A third and largely
unexplored mechanism is their release on lipoprotein
particles. Lipid-modiﬁed proteins on the exoplasmic face of
the plasma membrane might ﬁt well into the phospholipid
monolayer of such a particle, as demonstrated by the
presence of GPI-anchored CD59 in HDL particles [12]. These
lipoprotein particles might further transfer GPI-anchored
proteins onto other cells, resulting in a net intercellular
transfer. Interestingly, when transfected into cultured cells,
GPI-anchored proteins can be transferred between cells
[13 16]; this process was also observed in mice transgenic
for human CD59 [17]. Trypanosome surface GPI protein has
been observed on host erythrocytes [18], and retrograde
transfer of host GPI protein onto the parasite was found in
schistosomes [19]. It is not known how this transfer works
mechanistically nor whether lipoprotein particles are in-
volved.
We recently found that the lipid-linked morphogens
Hedgehog and Wingless associate with Drosophila lipoprotein
particles, and that their intercellular transport depends on
the presence of lipoproteins [20]. Similarly, parasites such as
schistosomes might utilize host lipoprotein particles as
carriers for their GPI-linked surface antigens. Here, we
demonstrate that parasite GPI-anchored glycoproteins are
released onto host lipoprotein particles that are taken up by
host cells via the low-density lipoprotein (LDL) receptor and
the Fc receptors. This intercellular transfer of parasite GPI-
anchored proteins to its host has important pathophysio-
logical implications.
Methods
Materials
Chemicals, unless indicated otherwise, were from Sigma (St.
Louis, Missouri, United States) and used in the highest purity
available. Silica TLC plates were from Merck (Darmstadt,
Germany), organic solvents were from Riedel de Hae ¨n
(Darmstadt, Germany), and cell culture media and reagents
were from Invitrogen (Breda, The Netherlands). Cell culture
plasticware was from Costar (Cambridge, Massachusetts,
United States). Phosphatidylinositol-speciﬁc phospholipase
C (PI-PLC) from Bacillus cereus was from Molecular Probes
(Eugene, Oregon, United States). Tran[
35S]label (.36 TBq/
mmol) was from ICN (Costa Mesa, California, United States).
[U-
14C]palmitic acid (18 TBq/mol) was from Amersham
(Buckinghamshire, UK). Ju ¨rgen Gent generously provided us
with a plasmid containing the human LDL receptor.
Antibodies
The synthetic peptide CIKAHDYKLLTKI-
LAARQLQDLFDNDKN, which corresponds to amino acids
29–55 from the GPI-anchored surface protein SM200 of S.
mansoni [21], was conjugated with its amino-terminal cysteine
to keyhole limpet haemocyanin, and used for immunization
of rabbits (Eurogentec, Seraing, Belgium). Antibodies to
SM200 were afﬁnity puriﬁed using the same peptide coupled
to Afﬁgel-15 columns (BioRad, Hercules, California, United
States). The mouse monoclonal antibody (mab) to SM200,
307D5 [4], was kindly provided by Karl Hoffmann (University
of Cambridge, UK). The mouse mab 120–1B10 to circulating
anodic antigen (CAA) from S. mansoni—which speciﬁcally
recognizes schistosomal glycoproteins (sGPs) carrying O-
linked GlcAb1–3GalNacb1–6(GlcAb1–3)GalNAcb1 repeating
units—was described previously [22,23]. The mouse mab 114–
5B1, which recognizes the schistosome-speciﬁc oligosacchar-
ide structure GalNacb1–4[Fuca1–2Fuca1–3]GlcNacb-R (or
LDN-DF), was described previously [24,25].
Polyclonal rabbit antisera recognizing the human LDL
receptor [26] and calreticulin [27] were a generous gift of
Ju ¨rgen Gent and Ineke Braakman (Utrecht University).
Blocking antibody against human FccRIIa was mab IV.3 from
Medarex (Annandale, New Jersey, United States). Rabbit anti-
human ApoA1 and ApoB were from Calbiochem (La Jolla,
California, United States), rabbit anti-mouse ApoA1 was from
Biodesign (Saco, Maine, United States). Rat mab 1D4B to
mouse LAMP-1 was from Santa Cruz Biotechnology (Santa
Cruz, California, United States). Biotinylation of afﬁnity-
puriﬁed antibodies with biotin-X succinimidyl ester (Molec-
ular Probes) was performed according to the vendor’s
instructions. Fluorescently labelled secondary goat antibodies
were obtained from Jackson ImmunoResearch Laboratories
(West Grove, Pennsylvania, United States). Horseradish
peroxidase-conjugated secondary goat antibodies were from
DAKO (Glostrup, Denmark).
Antibodies used in immuno-electron microscopy were
anti-120–1B10-biotin conjugate, rabbit anti-SM200-biotin,
rabbit anti-apolipoprotein B, goat anti-biotin conjugated to
10 nm gold (Aurion, The Netherlands) and 10 nm protein A-
gold (Cell Microscopy Center, Utrecht, The Netherlands)
Sera
Sera of S. mansoni-infected individuals were obtained from
the WHO/TDR Reference Serum Bank for African Schisto-
somiasis. Control sera were from donors with no known
history of schistosomiasis.
Heat-inactivated foetal calf serum (FCS) was delipidated
(DL-FCS) by solvent extraction. Serum was mixed with an
equal volume of a 2:1 mixture of diisopropyl ether:N-butanol,
stirred at room temperature for 30 min, and phases were
separated by centrifugation at 5,000 g for 30 min. The
aqueous phase was re-extracted as before with an equal
volume of diisopropyl ether, dialyzed against PBS, and ﬁlter-
sterilized. This treatment resulted in the total loss of intact
lipoprotein particles, as judged by the loss of apolipoprotein
A and B from the top fraction of a KBr gradient
centrifugation analysed by SDS-PAGE and Coomassie bril-
liant blue staining. The cholesterol content was reduced to
less than 5% of untreated serum, as determined by a
colorimetric assay kit (Boehringer-Mannheim, Indianapolis,
Indiana, United States).
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Release of Schistosoma GlycoproteinsCell Culture, Transfection, and Uptake Experiments
Peripheral blood from normal human volunteers was
collected in heparin tubes, and polymorphonuclear neutro-
phils (PMNs) were isolated by density gradient centrifugation
using Ficoll-Hypaque [28]. The neutrophils were divided into
4-ml samples with 10
6 cells/ml in RPMI 1640 medium
containing 25 mM Hepes (pH 7.2), 2 mM nonessential amino
acids, 1 mM sodium pyruvate, 2 U/ml interferon c, and 20%
heat-inactivated human serum. After cells were incubated for
8 h with 20% patient or control sera at 37 8C with 5% CO2,
they were washed extensively with ice-cold PBS, lysed in
reducing Laemmli sample buffer, and subjected to Western
blotting.
Mutant Chinese hamster ovary cells lacking the mature
LDL receptor (LDLA cells) [29] were kindly provided by Ineke
Braakman (Utrecht University, the Netherlands) and grown in
Ham’s F12 medium with 5% FCS, 2 mM glutamine at 37 8C
with 5% CO2. LDLA cells were transfected with the human
LDL receptor in pCDNA3 [26] or the empty vector using
Lipofectamine 2000. Transfectants were cultured in normal
culture medium containing 1 mg/ml geneticin. Stable cell
lines were obtained by subcloning individual colonies.
Positive clones were selected by immunoﬂuorescence micro-
scopy and tested for expression of hLDL-R by Western
blotting. LDLA cells were transfected with the human FccRIIa
expression vector FccRIIa-pRC-CMV [30] or the empty vector
using Lipofectamine 2000. Expression of FccRIIa was induced
by 5 mM sodium butyrate 14–16 h prior to experiment. For
uptake experiments, conﬂuent cells on 3-cm dishes, or
subconﬂuent cells on glass coverslips, were incubated with
Ham’s F12 medium containing 2 mM glutamine and 20%
human serum for 6 h at 37 8C with 5% CO2. Cell were washed
extensively with ice-cold PBS and subjected to either Western
blotting or immunoﬂuorescence microscopy as described
[31], except that the cells were examined with a Nikon D-
eclipse C1 confocal microscope using separate ﬁlters for each
ﬂuorochrome viewed (FITC: Lex ¼ 488 nm and Lem ¼ 515 LP;
Texas red: Lex ¼ 568 nm and Lem ¼ 585 LP). Single-labelled
cells with each primary/secondary antibody combination
were examined and conﬁrmed that no bleed-through
occurred for the given conditions.
Metabolic Labelling of Adult S. mansoni Worms
S. mansoni adult worms were collected by perfusion of the
hepatic portal system of golden hamsters at 7 wk after
infection with ; 500 cercariae per hamster [32]. About 100
adult worms pairs were incubated with 5 ml RPMI 1640
medium containing 100 mM Hepes (pH 7.2), 2 mM sodium
pyruvate, 100 U/ml penicillin, and 100 lg/ml streptomycin.
For radiolabelling of worm proteins and lipids, 18 MBq/ml
Tran[
35S]-label and 18 kBq/ml [U-
14C]palmitic acid were
added to the medium, respectively. After worms were
incubated for 24 h at 37 8C with 5% CO2, the medium was
subjected to isopycnic density centrifugation. The worms
were washed with ice-cold PBS, and the worm proteins and
lipids were analysed as described below.
Neutrophil Apoptosis and FACS Analysis
PMNs were isolated from healthy volunteers as described
and cultured in RPMI 1640 medium containing 20% control
or patient serum, or 10% serum preincubated with 10 mg of
rabbit anti-ApoB antibodies or rabbit IgG (control) for 30
min at room temperature, and immunocomplexes were
allowed to form. After 20 h of culture, cells were counted
and washed in binding buffer consisting of 10 mM Hepes, 150
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, and 1 mM MgCl2.
Annexin V FITC (BD Biosciences Pharmingen) was added to
the cells and incubated for 15 min at room temperature, and
cells were measured on a FACSCalibur (Becton Dickinson,
San Jose, California, United States) to determine the
percentage of dead cells. Survival was calculated as the
percentage of living cells relative to the input number of
PMNs.
Isopycnic Density Centrifugation and PI-PLC Treatment
Serum or medium was spun for 3 h at 39,000 rpm at 4 8Ci n
a SW41 rotor (Beckman). Pellet and supernatant were
designated as P120 and S120, respectively. In some cases,
the S120 was split in two equal fractions and either treated
with 4 U/ml PI-PLC or mock-treated for 6 h at 37 8C.
Lipoprotein particles were separated from soluble proteins
by isopycnic density centrifugation. In short, KBr was added
to S120 to a ﬁnal concentration of 0.33 g/ml, and the sample
was spun for 2 d at 39,000 rpm at 4 8C in a SW41 rotor. Six or
twelve fractions were taken from the top. The top and bottom
fractions had a density of 1.22 and 1.40 g/cm
3, respectively.
The proteins were precipitated with chloroform/methanol,
and the lipids in the chloroform phase were analysed
separately. Lipids were separated by thin-layer chromatog-
raphy using silica gel 60 plates and chloroform/methanol/25%
NH4OH (65:25:4 v/v) as running solvent. Radiolabelled spots
were detected by phosphor-imaging on a Storm phosphor-
imager. Spots were identiﬁed by comparison to standards and
quantiﬁed using the Imagequant Software (Molecular Dy-
namics, Sunnyvale, California). Radiolabelled proteins were
analysed by SDS-PAGE followed by autoradiography or by
Western blotting.
Immunoprecipitation
S120 was precleared during a 2-h incubation with 0.25
volumes of streptavidin-agarose or empty Sepharose beads. A
fraction of each supernatant was used to determine relative
amounts of ApoA1 and ApoB by Western blotting. The
remainder was incubated with biotinylated anti-rabbit SM200
or a mixture of biotinylated 120–1B10 and 114–5B1 anti-
bodies preadsorbed to streptavidin-agarose. For immunopre-
cipitations of human antibodies from serum, the samples
were incubated with protein A-Sepharose beads without
addition of a primary antibody. Immunoprecipitates were
washed at least ten times with ﬁve volumes of PBS containing
0.5% bovine serum albumin and once with ﬁve volumes of
PBS. Proteins were eluted from beads using either a
detergent-containing buffer (150 mM NaCl, 2 mM EDTA,
100 mM Tris-Cl [pH 8.3], 0.5% Nonidet P 40, 0.5% sodium
deoxycholate, and 0.1% SDS) or Laemmli sample buffer
containing 5% b-mercaptoethanol.
Immuno-Electron Microscopy
Lipoprotein particles were separated from the blood of
either the positive or the control patient by a KBr gradient.
Of this fraction 3-ll droplets were placed on carbon-coated
copper grids with a formvar ﬁlm and incubated for 30 min.
The particles attach to the formvar ﬁlm. After washing with
PBS, the particles were labelled as previously described [33]
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Release of Schistosoma Glycoproteinswith biotinylated primary antibodies followed by goat anti-
biotin directly coupled to gold. To detect human antibodies
on host lipoproteains, puriﬁed particles were labelled with
protein A-gold only.
Results
Schistosomes Release Proteins and Lipids on Lipoprotein
Particles
Adult schistosomes release proteins and lipids from their
surface into the circulation [34]. To investigate whether they
are present on lipoprotein particles, sera from patients
chronically infected with S. mansoni were cleared of parasite
remnants and membrane fragments by high-speed centrifu-
gation and analysed by isopycnic density centrifugation
(Figure 1A). The top fraction contained all lipoprotein
particles, whereas soluble proteins were found in fractions
of relatively higher density. Remarkably, several GPI-anch-
ored sGPs as well as the GPI-anchored surface protein SM200
selectively accumulated in the lipoprotein fraction of patient
but not control sera (Figure 1A, top lanes).
Next, we tested whether ApoB, the major protein constit-
uent of human LDL particles, could be coimmunoprecipi-
tated with antisera against sGP or SM200. To avoid effects
resulting from the presence of anti-Schistosoma antibodies in
patient serum (see below), we used biotinylated antibodies
and streptavidin-agarose for pull-downs throughout. ApoB
was coimmunoprecipitated from patient sera, but not from
control serum, by antibodies against both schistosomal
antigens (Figure 1B), indicating a physical association of
schistosomal GPI-anchored proteins with human lipoprotein
particles. The association of sGP was sensitive to treatment
with PI-PLC (Figure 1B, left), suggesting that they bound to
lipoprotein particles via the GPI anchors. Immunoprecipita-
tion of the GPI-anchored protein SM200 after PI-PLC
t r e a t m e n td i dn o tr e s u l ti nas i g n i ﬁ c a n tr e d u c t i o no f
recovered ApoB (Figure 1B, right), consistent with a previous
report that the GPI anchor of SM200 is resistant to PI-PLC
[35].
The localization of schistosomal proteins on lipoprotein
particles was further assessed by electron microscopy (Figure
2). Lipoprotein particles of 10–60 nm diameter were detected
in both control and patients sera by immunostaining against
ApoB (Figure 2E and 2F). No membranous fragments or
parasite remnants were detected in any of the samples.
Puriﬁed lipoprotein particles from patient serum contained
both sGP and SM200 (Figure 2B and 2D), which were lacking
in the control sample (Figure 2A and 2C). Note the close
proximity of gold particles and lipoprotein particles; no gold
dot is found that is not associated with a particle, ruling out
background binding to nonparticulate material or to a
possible soluble, free form of the antigen. We performed
statistical analysis on the data in Figure 2A and 2B. In three
independent ﬁelds of different patients or control individuals
we counted total lipoprotein particles (altogether 9,700 in
control and 5,900 in patient ﬁelds) and gold particles (two
Figure 1. Lipoprotein Particles of Infected Humans Contain Schistosomal
Surface Proteins
(A) Lipoprotein particles of control and patient sera were separated from
soluble proteins by KBr density gradient centrifugation. Proteins from
gradient fractions were analysed by SDS-PAGE and Western blotting
against schistosome-specific glycoproteins (sGP), schistosomal GPI-
anchored protein SM200, and human apolipoprotein B (ApoB). Note
the presence of sGP and SM200 in the top fractions that contain the
lipoprotein particles. Strong background staining is due to high protein
concentrations in serum; data are representative of six different patient
sera.
(B) Control (C) and patient (P1 and P2) sera were mock-treated ( )o r
treated with PI-PLC (þ) and subjected to immunoprecipitation with
biotinylated antibodies against either sGP (left) or SM200 (right).
Immunocomplexes were isolated with streptavidin-agarose beads and
analysed by SDS-PAGE and Western blotting for ApoB. Streptavidin
beads alone did not pull down ApoB in patient sera (unpublished data).
Antibodies were raised against a peptide sequence or a common
glycoconjugate and recognize the protein irrespective of the presence of
the diacylglycerol moiety.
DOI: 10.1371/journal.pmed.0030253.g001
Figure 2. Schistosomal GPI-Linked Surface Proteins Directly Bind to
Lipoprotein Particles
Lipoprotein particles isolated from control (A, C, and E) and patient (B, D,
and F) sera were stained by immunogold labelling for schistosome-
specific glycoconjugates using biotinylated antibody 120–1B10 (A and B),
anti-SM200 (C and D), and anti-ApoB (E and F) and goat anti-biotin
conjugated to 10 nm gold and visualized by electron microscopy. Bar,
100 nm. Data are representative of three infected individuals.
DOI: 10.1371/journal.pmed.0030253.g002
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Release of Schistosoma Glycoproteinscontrols, 48 patients) to give values of 0.5 6 0.5 gold/1,000
lipoprotein particles for control and 8.2 6 2 gold/1,000
lipoprotein particles for patients (p , 0.001).
Transfer of Schistosomal Proteins onto Lipoprotein
Particles In Vitro Depends on Intact Host Lipoprotein
Particles
To reconstitute the transfer of GPI-anchored proteins onto
lipoprotein particles outside the host organism, we kept adult
worms in culture medium supplemented with [
35S]Cys/Met
and [
14C]palmitate and analysed the medium for radio-
labelled parasite proteins and lipids. After worms and
membrane fragments were removed by high-speed centrifu-
gation, about 2% of the radioactive proteins were found in
the high speed supernatant S120 (unpublished data). The
lipoprotein fraction was separated from the rest of the S120
by isopycnic density centrifugation on a KBr gradient. Figure
3A shows the two top gradient fractions of the experiment
done in normal or in delipidated medium; lipoproteins
accumulate in the very top fraction 1. At least six distinct
parasite proteins were found in this lipoprotein particle
fraction (Figure 3A, full, fraction 1), suggesting association
with lipoprotein particles. Incubation of schistosomes in
solvent-extracted delipidated medium, free of lipoprotein
particles, resulted in a loss of parasite proteins from the top
fraction of the gradient (Figure 3A, DL, fraction 1).
Schistosomal lipids, synthesized from the added [
14C]palmi-
tate, were also found in the top fraction of the full, but not
the delipidated medium (Figure 3A, [
14C]-lipids). This
indicates that S. mansoni transfers not only protein but also
lipids onto host lipoprotein particles. Mass spectrometrical
analysis conﬁrmed the presence of schistosome-speciﬁc C20:1
fatty acid on phosphatidylcholine in the lipoprotein fraction
of patient, but not of control serum (unpublished data).
Both SM200 and sGP were found in the lipoprotein
fraction of the same culture medium (Figure 3B), indicating
that at least some of the radioactive schistosomal proteins in
the lipoprotein fraction are GPI-anchored. This association
was sensitive to PI-PLC treatment prior to density centrifu-
gation, which caused sGP, but not SM200, to disappear from
the top fraction (Figure 3B, full þ), consistent with the
observations made with patient sera (Figure 1). We conclude
that the transfer of GPI-linked schistosomal surface proteins
to lipoprotein particles can take place in vitro, requires the
presence of host lipoprotein particles in the serum, and is
independent of lipoprotein turnover by the host cells.
LDL Receptor-Dependent Uptake of Schistosomal
Glycoproteins
To distribute lipids to peripheral tissues, LDL particles are
constantly endocytosed by recipient cells. Thus, schistosomal
antigens on lipoprotein particles should spread not only in
the circulation, but also into host cells in the periphery of the
body. To address this possibility, CHO-LDLA cells, which lack
a functional LDL receptor [29], were stably retransfected with
the human LDL receptor or were mock-transfected and
incubated with medium containing control (C in Figure 4) or
patient (P1 and P2 in Figure 4) serum. As shown by
immunoblotting of cell lysates, only cells with the LDL
receptor (þin Figure 4), but not mock-transfected controls ( 
Figure 3. Schistosomes Transfer Glycoproteins and Lipids to Lipoprotein
Particles In Vitro
Adult S. mansoni worms were incubated overnight in medium with [
35S]-
amino acids and [
14C]-palmitic acid in the presence of normal (full) or
delipidated (DL) FCS, and media were precleared by high-speed
centrifugation.
(A) Media were subjected to KBr density gradient centrifugation, and
fractions were analysed for schistosomal proteins by SDS-PAGE followed
by autoradiography (top) and for schistosomal lipids by TLC followed by
autoradiography (bottom). The top and second top fractions of the
gradients are shown. Note the presence of prominent protein bands at
25, 70, and 250 kDa in the top fraction of full but not of delipidated
medium.
(B) Top fractions from KBr density gradient centrifugations of mock-
treated (  PI-PLC) or PI-PLC treated (þ PI-PLC) normal media (full) or
delipidated media (DL) were analysed for schistosome-specific glyco-
proteins (top) and for SM200 (middle) by Western blotting and for
schistosomal lipids by thin-layer chromatography followed by auto-
radiography (bottom).
DOI: 10.1371/journal.pmed.0030253.g003
Figure 4. The LDL Receptor Pathway Can Mediate Endocytosis of
Schistosomal Surface Proteins
CHO-LDLA cells lacking ( ) or retransfected with (þ) LDL receptor were
incubated with control (C) or patient (P1 and P2) sera. Cell lysates were
subjected to SDS-PAGE and Western blotting for endocytosed SM200 or
schistosome-specific glycoproteins. As loading controls, the medium was
probed for ApoB, and the cells for calreticulin and for the presence of
transfected LDL-receptor.
DOI: 10.1371/journal.pmed.0030253.g004
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Release of Schistosoma Glycoproteinsin Figure 4) were able to take up SM200 and other
schistosomal glycoproteins from patient serum. To follow
the intracellular localization of the internalized material,
confocal immunoﬂuorescence microscopy was performed
(Figure 5). Cells with (LDLR in Figure 5) or without (LDLA
in Figure 5) the LDL receptor were incubated in patient
serum, then stained for either sGP or SM200 (red) and
counterstained for the lysosomal marker protein LAMP-1
(green). As a negative control, cells with LDL receptor were
also incubated in control serum and stained for the same
markers. Both sGP and SM200 became internalized into
structures positive for the lysosomal marker protein LAMP-1
(LDLR þ P in Figure 5), as demonstrated by a virtually
complete colocalization of the two markers (overlay, yellow).
These lysosomes were characteristically increased in size
(diameter mean 6 standard deviation: control, 0.4 6 0.2 lm;
patient serum, 1.0 6 0.3 lm; n ¼ 38 each; p , 0.001) and
decreased in number compared to cells that either expressed
no receptor (Figure 5, LDLA þ P) or expressed receptor but
received control serum (Figure 5, LDLRþC). A small amount
of schistosomal antigens was also internalized in LDLA cells
(Figure 5, LDLA þ P), but did not colocalize with the
lysosomal marker.
Antibody-Antigen Complexes on Lipoprotein Particles in
Patient Serum
The presence of schistosomal antigens on host lipoprotein
particles enables host antibodies to bind indirectly to
lipoproteins via the attached antigens. In patient serum, but
not in control serum, ApoB was precipitated by IgG-binding
protein A beads without the addition of antibodies against
schistosomal antigens, demonstrating binding of host anti-
bodies to lipoprotein particles (Figure 6A). Ultrastructural
analysis (Figure 6B) also showed human IgG on lipoprotein
particles from patient serum.
This result suggests that cells expressing low-afﬁnity IgG
receptors such as FccRIIa could speciﬁcally bind and
endocytose liporotein particles from infected patients. To
study this possibility, we transfected CHO-LDLA cells with
FccRIIa and analysed the amount of ApoB that was
endocytosed from control and patient serum (Figure 6C).
Presence of the receptor caused an increase in endocytosed
lipoprotein particles from patient but not from control
serum.
Neutrophils Accumulate Lipids from Patient Serum by IgG
Receptor-Mediated Lipoprotein Uptake
Human PMNs physiologically express the FccIIRa receptor
and might endocytose antibody-lipoprotein complexes from
schistosomiasis patient serum. We found that freshly isolated
human neutrophils took up lipoprotein particles from
patient serum (P1 and P2 in Figure 7A), but not from control
serum (Figure 7A and 7C). This uptake actually depended on
the FccIIRa receptor, since it could be blocked by addition of
a blocking antibody, mab IV.3 [36], against this receptor
(Figure 7B). This result suggests that clearance by the immune
system is one of the reasons for the low levels of lipoprotein
particles observed in schistosomiasis patient circulation [37].
Uptake of lipoprotein particles by neutrophils delivers not
only apolipoproteins but also the associated lipids, which
could affect the cells’ lipid balance. To address this question,
we stained neutrophils that had been incubated in control or
patient serum with a dye, Nile red, that speciﬁcally detects
accumulations of neutral lipid. Increased accumulations of
neutral lipid in multiple round structures, likely lipid
droplets, were found after incubation in patient serum (Pat,
Figure 7C), again inhibited by the presence of mab IV.3
during the incubation (Pat þ mab IV.3, Figure 7C). To test if
this neutral lipid accumulation also occurs in the acute
disease state, we isolated PMNs from control or S. mansoni-
infected hamsters and examined these cells by Nile red
Figure 5. Endocytosed Schistosomal Surface Proteins Accumulate in
Enlarged Lysosomes
CHO-LDLA cells lacking (LDLA) or re-transfected with LDL receptor (LDLR)
were incubated with control (C) or patient (P) sera, fixed, and processed
for immunofluorescence microscopy. Localization of schistosomal
glycoproteins (sGP, red) or SM200 (SM200, red) and of the lysosomal
marker protein LAMP-1 (green) was imaged by confocal laser fluores-
cence microscopy. Note the enlarged lysosomes in cells (LDLR þ P) that
take up schistosomal proteins on lipoprotein particles. Bars, 10 lm.
DOI: 10.1371/journal.pmed.0030253.g005
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Release of Schistosoma Glycoproteinsstaining. We found an accumulation of lipid in cells of
infected but not of control animals (Figure 7D).
If this uptake of antibody-antigen-lipoprotein complex
were harmful to the neutrophils, it might contribute to the
parasites’ evasion of host immune response. We cultured
freshly isolated PMNs with control or patient serum, which
led to apoptosis of a major fraction of the cells under both
conditions, with a signiﬁcantly reduced survival in patient
serum (left bar graph, Figure 7E). To test whether reduced
survival could be caused by antibody-lipoprotein complexes,
we repeated the experiment in normal serum that was
preincubated with control antibodies or anti-ApoB anti-
bodies, to allow anti-ApoB antibodies to bind directly to
lipoprotein particles. This treatment resulted in nearly
complete apoptosis (right bar graph, Figure 7E), suggesting
that antibody-lipoprotein complexes indeed destroy the most
abundant phagocytes in the blood and thereby inhibit the
immune response.
Presence of GPI-Linked Surface Antigens on Lipoproteins
is a Widespread Phenomenon
The potential to release GPI-linked surface antigens on
lipoprotein particles may not be restricted to schistosomes
but shared by other blood-dwelling parasites such as
Trypanosoma brucei, whose VSG surface proteins have been
found on host erythrocytes [18]. Conditioned medium of
cultivated T. brucei was precleared by high-speed centrifuga-
tion and analysed by isopycnic density gradient centrifuga-
tion (Figure 8). The major GPI-linked surface antigen VSG221
accumulated in the top fraction of the gradient (culture PI-
PLC, Figure 8A) and was sensitive to treatment with PI-PLC
(culture þ PI-PLC, Figure 8A). VSG221 was speciﬁcally
coimmunoprecipitated from the medium by antibodies
against mouse ApoA1 (Figure 8B), and was also sensitive to
pretreatment with PI-PLC. ApoA1 was chosen because, in
contrast to human serum, mouse serum HDL levels are much
higher than LDL levels. We concluded, also, that VSG221
associates with lipoprotein particles via its GPI-anchor.
Discussion
GPI-Anchored Proteins as Mobile Intercellular Elements
GPI is a complex glycolipid structure that acts as a
membrane anchor for many cell surface proteins of eukar-
yotes [5]. Release of GPI-anchored proteins from the cell
surface by speciﬁc phospholipases may play a key role in
regulation of their surface expression and functional proper-
ties. It has been demonstrated that GPI-anchored proteins
can undergo intercellular transfer in vitro [13–16]. The
present study shows, to our knowledge for the ﬁrst time,
release of endogenous parasite GPI-anchored proteins to
human lipoproteins. The lipoprotein complexes formed were
then transferred to host cells. In vitro and in vivo data
strongly suggest that this process is connected to the
pathology of parasite infection. The mechanism of transfer
may either be spontaneous diffusion, enhanced by tight
binding of human lipoproteins to the schistosome surface
[38], or be supported by an unknown mechanism at the
plasma membrane or in the endocytic pathway. In T. brucei,
both GPI-linked surface proteins and LDL share the same
endocytic pathway [39], suggesting that transfer takes places
in endocytic or recycling organelles. Identiﬁcation of the
mechanism of transfer (which would be a potential drug
target) and study of its regulation, are important goals of
future research. The principle demonstrated here—GPI-
protein transfer between organisms—may also apply to prion
diseases such as bovine spongiform encephalopathy and
Creutzfeldt-Jakob disease, which are caused by infective
GPI-anchored proteins. Intercellular transfer of prion pro-
tein has been observed in cell culture [15], but it was claimed
that spreading occurs on exosomes [40]. In light of our
ﬁndings, it seems worthwhile to investigate the role of
lipoproteins in prion protein spreading in infected animals.
Immunologic and Pathophysiologic Aspects
To evade the immune response, parasites have developed
various strategies [41], such as the rapid antigenic variation of
trypanosomal surface VSG proteins [42]. It is unclear how
Figure 6. Lipoproteins from Infected Humans Are Decorated with
Antibodies and Can Be Endocytosed Via the FccRIIa Receptor
(A) Control (C) and patient (P1 and P2) sera were incubated with protein
A-Sepharose beads. Bound material was eluted and subjected to SDS-
PAGE and Western blotting for ApoB.
(B) Lipoprotein particles were isolated from control and patient sera,
stained for endogenous antibodies present on lipoprotein particles using
protein A-gold, and subjected to electron microscopy.
(C) CHO-LDLA cells lacking ( ) or transfected with (þ)F C cRIIa receptor
were incubated with control (C) or patient (P1 and P2) sera. Cell lysates
were subjected to SDS-PAGE and Western blotting for endocytosed
ApoB (ApoB [Cells]). A proteolytic fragment [56] of ApoB was detected at
;80 kDa. As load controls, the medium was probed for ApoB (ApoB
[Medium]), and the cells for calreticulin.
DOI: 10.1371/journal.pmed.0030253.g006
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in particular adult worms, which can live for years in the
portal vein [2]. It appears that release of antigens is a major
factor determining the immune response against schisto-
somes [43,44], but the effects of these released antigens are
subject to dispute [45,46]. In general, released antigens have
negative modulating effects on the immune system, such as
blocking of antibodies and effector cells, induction of
tolerance, or activation of suppressor cells. Also, it has been
noted that the immune response against a lipopeptide
construct that can bind to surface lipids is different from
that against the corresponding free peptide for both a viral
[47] and a schistosomal antigen [48]. We also speculate that
travelling on a lipoprotein surface would change the
antigenic properties of a protein, although so far we have
found only GPI-linked proteins and other lipidated proteins
(Hedgehog and Wingless [20]) on lipoprotein surfaces. Since
these proteins are also normally found on cell surface lipids
or membrane fragments, uptake, processing, and presenta-
tion by antigen-presenting cells should not be grossly altered.
What seems more important is that spreading of antigens
via lipoproteins intermixes two pathways—antigen phagocy-
tosis and lipid turnover—that normally are kept separate
from each other. On the one hand, cells that are not
specialized in antigen phagocytosis will endocytose schisto-
somal surface antigens via the LDL receptor pathway. As an
example, endocytosis of lipoprotein particles from schisto-
somiasis patient serum changed the morphology of lysosomes
in ﬁbroblast cells, which probably reﬂects problems in the
lysosomal degradation of schistosomal glycoconjugates. Sim-
ilar lysosomal phenotypes are observed in glycolipid storage
diseases such as Fabry’s and Gaucher’s disease, with accumu-
lations in kidney tubule cells and cardiac muscle [49], or in
macrophages [50], respectively. In schistosomiasis, lysosomal
abnormalities or defects have not been described so far. On
the other hand, immune cells that are specialized for
endocytosis of antibody-antigen complexes will attack lip-
oprotein particles. Neutrophils, which are the most impor-
tant phagocytes of the blood, take up lipoproteins of
schistosomiasis patients via FccRIIa receptors, as demonstra-
ted in this study. This should contribute to the reduction of
lipoprotein levels in patients [37], which has the interesting
secondary effect of protecting the host from atherosclerosis
[51,52]. With the endocytosed lipoproteins, these cells take up
large amounts of lipids, giving rise to intracellular accumu-
lation of lipids, shown in Figure 7C and 7D both in vitro and
in vivo. Damage induced by the lipid accumulation may
contribute to neutrophil apoptosis and low neutrophil counts
in schistosomiasis patients [53], supporting immune evasion
by the parasite. In support of this, schistosomiasis patient
serum promotes neutrophil apoptosis. We can mimic this
effect by using normal serum to which anti-ApoB antibodies
Figure 7. Lipoproteins of Patient Serum Are Endocytosed by Neutrophils and Lead to Intracellular Accumulation of Neutral Lipids and Enhanced
Neutrophil Apoptosis
(A, B, and C) Freshly isolated human PMNs were incubated for 16 h with control (C) and patient (P, P1, P2, and Pat) sera. For (A and B), cells were washed
extensively and cell lysates probed for ApoB and LDL-receptor by SDS-PAGE and Western blotting. A proteolytic fragment [56] of ApoB was detected at
;80 kDa. LDL receptor served as a load control. For (B and C), the FccRIIa blocking mab IV.3 was added during the incubation (P1þ[B]; Pat.þmab IV.3
[C]). For (C), cells were fixed, stained with Nile Red and subjected to confocal fluorescence microscopy.
(D) PMNs of control or schistosome-infected hamster were stained with Nile Red and subjected to confocal fluorescence microscopy. Data are
representative of four infected and control animals.
(E) PMNs were incubated for 20 h with 20% (left) or 10% (right) control or patient serum as indicated. For the right bar graph, 10 lg/ml normal rabbit
antibody (Control) or anti-ApoB antibody were preincubated with control serum, and subsequently added to PMNs. Cells were counted before and after
incubation with serum, stained with Annexin V-FITC (which indicates apoptosis), and analysed by FACS. Results are expressed as percentage of Annexin
V-negative cells, relative to the number of cells before incubation with serum. Statistical analysis was done by Student’s t-test, ** p , 0.01.
DOI: 10.1371/journal.pmed.0030253.g007
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Release of Schistosoma Glycoproteinswere added, which effectively is a treatment with a lip-
oprotein-antibody complex similar to the ones generated in
schistosomiasis by antibody-GPI-protein complexes on the
lipoprotein particles. Peripheral immunocomplexes in schis-
tosomiasis also act on B cells, which also carry the Fc
receptor, to reduce proliferation and MHC class II expression
[54]. Other cells that endocytose antigen via Fc receptors are
macrophages and dendritic cells, which also are exposed to
antigen-loaded lipoproteins. Released schistosomal antigens
strongly modulate their behavior to favour a Th-2 type
immune response [2]. It is tempting to speculate that, similar
to the alterations of lysosomal structure in ﬁbroblast in
response to antigen-loaded lipoproteins, antigen processing
by these specialized cells might also be altered. Since
lysosomal activity is an important parameter inﬂuencing
efﬁcient antigen presentation [55], this might ultimately
contribute to a modiﬁed immune response.
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Editors’ Summary
Background. More than 200 million people live in a close but uneasy
alliance with schistosomes, a type of parasitic worm. Like many parasites,
schistosomes have a complicated life cycle. They start life by reproducing
in fresh-water snails. The snails release free-swimming, infectious
parasites, which burrow into the skin of people who swim in the water.
The parasites then migrate to the veins draining the gut and mature into
10–20 mm-long adult worms. The worms mate and lay eggs, some of
which pass into the feces and so back into water where they hatch and
infect fresh snails. Schistosomiasis does not kill many people but it does
cause serious health problems. Most of these are caused by the human
immune system responding to eggs that get trapped in the veins of the
liver, spleen, and gut. Immune cells recognize proteins on the eggs as
foreign and organize a hard shell of immune cells and tough fibres
around the egg. Eventually, these fibres block the blood vessels in the
liver, spleen, and gut, causing locally raised blood pressure, organ
damage, and potentially fatal bleeding.
Why Was This Study Done? Although the immune system mounts a
vigorous attack against schistosome eggs, the parasites themselves
somehow evade the immune response—adult worms pull off this feat of
‘‘invisibility’’ for years. The researchers who did this study wanted to find
out whether the release of glycoproteins (proteins decorated with
sugars) from the surface of the schistosome worms is involved in this
immune evasion in some way. These glycoproteins (which are anchored
to the parasite’s surface by a structure called a GPI-anchor; GPI stands for
glycosyl-phosphatidylinositol, a sort of fat or lipid) are the major antigens
of schistosomes—the molecules that the immune system normally
recognizes on foreign intruders.
What Did the Researchers Do and Find? The researchers first showed
that GPI-anchored schistosomal glycoproteins are released into the
circulation of patients and there become attached to human lip
oproteinparticles (water-soluble carrier molecules that take fats around
the body). Then, using cells grown in the laboratory, the researchers
discovered that lipoprotein particles loaded with parasite glycoproteins
could enter mammalian cells through an interaction with a protein called
the low-density lipoprotein receptor, which normally helps cells absorb
the lipids needed to make membranes. Once in the cell, the parasite
glycoproteins travelled to cellular regions called lysosomes, which they
seemed to disrupt. In addition, the researchers found that the parasite
glycoproteins could enter mammalian cells by a second route: This
involved the glycoproteins being taken up by neutrophils (a type of
immune cells). Many of these neutrophils then died, possibly because of
the large amount of lipid they accumulated.
What Does This Mean? These results provide some tantalising clues to
how schistosomes might evade the immune response. First, just binding
to lipoprotein particles might change how they are seen by the immune
system (possible they are not as clearly recognized as foreign substances)
and weaken the immune response against them. On the other hand, the
damage done to neutrophils by lipid accumulation might also contribute
to how schistosomes hide in the human hosts. Neutrophils are an
important type of immune cell, and their destruction could compromise
the immune system’s response to schistosomes. Furthermore, although
the researchers do not investigate this possibility, other cells of the
immune system that have might also take up these lipids and be
damaged. Finally, even if immune cells are not killed outright by lipid
accumulation, disruption of their lysosomes might also affect how well
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Release of Schistosoma Glycoproteinsthe immune system recognizes schistosomes as foreign. The full details of
the complex interplay between schistosomes and their hosts remain a
mystery, but these results provide intriguing new avenues to explore that
might eventually suggest new treatments for schistosomiasis.
Additional Information Pleaseaccess these websites viathe onlineversion
of this summary at http://dx.doi.org/10.1371/journal.pmed.0030253.
  World Health Organization information on schistosomiasis
  US Centers for Disease Control and Prevention information for the public
and for professionals on schistosomiasis
  MedlinePlus encyclopedia entry on schistosomiasis
  Wikipedia page on schistosomiasis (note: Wikipedia is a free online
encyclopedia that anyone can edit)
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